Markets

Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients

Jul 30, 2026 · 06:22 AM ET· updated 3h ago

At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales.The guidance from NICE states that

Why It Matters

Cytokinetics got permission to sell a heart medicine called MYQORZO in the UK, and UK doctors now recommend it for patients who need it. This is good news because it means more people in a new country can use the medicine, which helps the company grow.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CYTK78.71

+0.32 (+0.41%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.